Wockhardt

Wockhardt Limited (NSE: WOCKPHARMA; BSE: 532300), commonly "Wockhardt," is an Indian pharmaceutical and biotech company founded in 1967 by Dr. Habil Khorakiwala and headquartered at Wockhardt Towers, Bandra-Kurla Complex, Mumbai. It is publicly listed on the BSE and NSE (listed since February 2000) and is not a subsidiary; the Khorakiwala family and related entities hold significant stakes. Sources vary on size: stockanalysis.com lists roughly 2,564 employees, while PitchBook lists about 4,084; market capitalization has been reported in the range of roughly ₹300 billion (~US$3 billion) in 2026, with trailing revenue around US$375 million (FY ending March 2026). Treat these figures as approximate and source-dependent.

Operations are concentrated in generic and branded pharmaceuticals and biotechnology, chiefly anti-infectives and diabetes care. Reported product lines include novel antibiotics (zidebactam/cefepime, nafithromycin), recombinant insulin analogs and GLP-1 products (Glaritus, Wosulin, insulin aspart), erythropoietin, vaccines, and insulin delivery devices, plus active pharmaceutical ingredients and finished formulations sold in India, the US, Europe and emerging markets. It has historically operated manufacturing and R&D sites in India, the UK, Ireland and elsewhere, and US subsidiaries including Wockhardt USA LLC and Morton Grove Pharmaceuticals, Inc.

Litigation posture: Across the tracked data, Wockhardt appears once, solely as a defendant (0 plaintiff cases) — the profile of an operating company being sued rather than a patent assertion entity. The single tracked matter sits in the U.S. District Court for the Northern District of California, not a plaintiff-friendly Texas venue.

Notable case: In re Xyrem (Sodium Oxybate) Antitrust Litigation (N.D. Cal., MDL No. 2966), in which Wockhardt, Wockhardt USA, and Morton Grove were named among generic-manufacturer defendants alongside Jazz Pharmaceuticals and other generics. The claims center on patent-settlement agreements allegedly delaying generic sodium oxybate; Wockhardt was voluntarily dismissed without prejudice from one related action in January 2021 under a tolling agreement. This is an antitrust matter with underlying patent-settlement context, not a patent infringement suit.